DS-5565 + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Fibromyalgia
Conditions
Fibromyalgia
Trial Timeline
Jun 26, 2015 → Jul 6, 2017
NCT ID
NCT02496884About DS-5565 + Placebo
DS-5565 + Placebo is a phase 3 stage product being developed by Daiichi Sankyo for Fibromyalgia. The current trial status is completed. This product is registered under clinical trial identifier NCT02496884. Target conditions include Fibromyalgia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02496884 | Phase 3 | Completed |
| NCT02318706 | Phase 3 | Completed |
Competing Products
20 competing products in Fibromyalgia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| DS-5565 + Pregabalin + Placebo tablet + Placebo capsule | Daiichi Sankyo | Phase 3 | 77 |
| DS-5565 | Daiichi Sankyo | Phase 3 | 77 |
| DS-5565 + Pregabalin + Placebo tablet + Placebo capsule | Daiichi Sankyo | Phase 3 | 77 |
| DS-5565 + Pregabalin + Placebo tablet + Placebo capsule | Daiichi Sankyo | Phase 3 | 77 |
| ASP8062 + Placebo | Astellas Pharma | Phase 2 | 52 |
| ASP0819 + Placebo | Astellas Pharma | Phase 2 | 52 |
| Duloxetine | Shionogi | Phase 3 | 77 |
| Duloxetine 60 mg + Placebo | Shionogi | Phase 3 | 77 |
| zonisamide | Eisai | Approved | 85 |
| ONO-1110 + Placebo | Ono Pharmaceutical | Phase 2 | 52 |
| Duloxetine | Eli Lilly | Approved | 85 |
| duloxetine hydrochloride + placebo | Eli Lilly | Approved | 85 |
| duloxetine | Eli Lilly | Phase 3 | 77 |
| Duloxetine + placebo | Eli Lilly | Phase 3 | 77 |
| Duloxetine + Placebo | Eli Lilly | Phase 3 | 77 |
| Duloxetine + Placebo | Eli Lilly | Approved | 85 |
| Treatment for Fibromyalgia | Eli Lilly | Pre-clinical | 23 |
| Duloxetine + Placebo | Eli Lilly | Phase 3 | 77 |
| duloxetine + placebo | Eli Lilly | Phase 3 | 77 |
| Eszopiclone + placebo | Sumitomo Pharma | Approved | 85 |